Nine-month results of Sartorius Stedim Biotech

Author's Avatar
Oct 20, 2021

- Sales revenue up 56.2 percent to 2,109 million euros; underlying EBITDA margin 36.3 percent

- Dynamic and profitable organic growth; significant demand momentum generated by the production of coronavirus vaccines as well as strong development of acquisitions

- Forecast raised at the beginning of July for 2021 confirmed

PR Newswire